Cilnidipine + Metoprolol Succinate (Metoprolol Tartrate) + Telmisartan is a combination medicine containing Cilnidipine, Metoprolol Succinate, and Telmisartan. It is primarily used to manage high blood pressure (hypertension) and related cardiovascular conditions. Cilnidipine relaxes blood vessels, Metoprolol slows the heart rate, and Telmisartan blocks the effects of angiotensin II, thereby improving blood flow. This triple combination helps in effective blood pressure control and reduces the risk of heart attack and stroke when taken as prescribed by a doctor.

Cilnidipine + Metoprolol Succinate (Metoprolol Tartrate) + Telmisartan is a fixed-dose triple combination medication used in the treatment of hypertension, especially in patients who require multiple drugs for adequate blood pressure control. It contains Cilnidipine, Metoprolol Succinate, and Telmisartan, each acting through different mechanisms to provide synergistic effects.

Cilnidipine is a calcium channel blocker (CCB) that inhibits L-type and N-type calcium channels, leading to relaxation of vascular smooth muscles and reduction in peripheral resistance. This helps in lowering blood pressure without causing excessive reflex tachycardia.

Metoprolol Succinate is a selective beta-1 adrenergic blocker that reduces heart rate, myocardial contractility, and cardiac output. It reduces the workload on the heart and is particularly useful in patients with hypertension and heart disease.

Telmisartan is an angiotensin II receptor blocker (ARB) that prevents vasoconstriction and aldosterone secretion by blocking angiotensin II receptors. This results in blood vessel dilation and reduced blood pressure.

This triple combination is often prescribed in patients with uncontrolled hypertension despite dual therapy. It not only helps in effective blood pressure management but also provides cardiovascular protection by reducing the risk of stroke, myocardial infarction, and kidney damage. Regular monitoring and adherence to treatment are essential for optimal outcomes.

• Management of high blood pressure (hypertension)

• Prevention of cardiovascular complications such as heart attack and stroke

• Used in patients with resistant or uncontrolled hypertension

• Helps reduce the workload on the heart

• Protects against kidney damage in hypertensive patients

• Improves blood circulation

• Used in patients with co-existing heart conditions

• Cilnidipine + Metoprolol Succinate (Metoprolol Tartrate) + Telmisartan provides effective blood pressure control by combining three medicines with different mechanisms of action. This ensures better and sustained reduction in blood pressure levels.

• It reduces the risk of serious cardiovascular events such as stroke, heart attack, and heart failure when used regularly.

• The combination improves patient compliance by reducing the need to take multiple separate medications.

• It also helps protect vital organs such as the heart, kidneys, and blood vessels from long-term damage caused by uncontrolled hypertension.

Common side effects

• Dizziness or lightheadedness

• Fatigue or weakness

• Headache

• Slow heart rate (bradycardia)

• Swelling of ankles or feet (oedema)

• Flushing

Uncommon side effects

• Low blood pressure (hypotension)

• Nausea or vomiting

• Cold extremities (hands and feet)

• Sleep disturbances

• Shortness of breath

• Increased potassium levels

Serious side effects (seek immediate medical attention)

• Severe hypotension or fainting

• Irregular heartbeat or severe bradycardia

• Worsening heart failure symptoms

• Kidney function impairment

• Severe allergic reactions (rash, swelling, breathing difficulty)

• If any side effects persist or worsen, consult your doctor immediately.

• Take Cilnidipine + Metoprolol Succinate (Metoprolol Tartrate) + Telmisartan exactly as prescribed by your doctor

• Swallow the tablet whole with a glass of water

• Do not crush, chew, or break the tablet

• Take it at the same time each day for better results

• Can be taken with or without food

• Do not stop taking the medicine suddenly without consulting your doctor

• Monitor your blood pressure regularly

• Avoid alcohol during treatment

Cilnidipine + Metoprolol Succinate (Metoprolol Tartrate) + Telmisartan works through a combination of three active components. Cilnidipine blocks calcium channels in blood vessels, causing vasodilation and reduced peripheral resistance.

Metoprolol Succinate selectively blocks beta-1 receptors in the heart, reducing heart rate and cardiac output, thereby lowering blood pressure.

Telmisartan blocks angiotensin II receptors, preventing vasoconstriction and reducing fluid retention. This leads to relaxation of blood vessels and improved blood flow.

Together, these mechanisms provide effective and sustained blood pressure control and cardiovascular protection.

• Take medicine regularly at the same time each day

• Do not skip doses

• Monitor blood pressure frequently

• Follow a low-sodium diet

• Avoid smoking and alcohol

• Inform the doctor about all other medications

• Store below 25°C in a cool and dry place

• Keep away from moisture and sunlight

• Keep out of reach of children

• Do not use after the expiry date

Cilnidipine + Metoprolol Succinate (Metoprolol Tartrate) + Telmisartan can be taken with or without food. However, certain dietary factors may influence its effectiveness. High potassium-containing foods may increase potassium levels when taken with Telmisartan. Alcohol may enhance hypotensive effects and increase dizziness.

Key interactions include:

• Avoid excessive potassium-rich foods (bananas, coconut water)

• Limit salt intake for better blood pressure control

• Avoid alcohol, as it may increase dizziness

• Maintain a balanced, heart-healthy diet

• Stay hydrated

Cilnidipine + Metoprolol Succinate (Metoprolol Tartrate) + Telmisartan may interact with several medications, affecting its safety and effectiveness.

Important drug interactions include:

• Other antihypertensive drugs may cause excessive hypotension

• Beta-blockers or calcium channel blockers – additive cardiac effects

• Potassium supplements or diuretics – increased risk of hyperkalemia

• NSAIDs – reduced antihypertensive effect

• Antidiabetic drugs may mask hypoglycemia symptoms
• Digoxin – may affect heart rhythm

Drug–Disease Interactions of Cilnidipine + Metoprolol Succinate (Metoprolol Tartrate) + Telmisartan

This medicine should be used cautiously in patients with certain medical conditions. Its components may affect heart, kidney, and liver functions.

Use with caution in the following conditions:

• Kidney disease – risk of worsening renal function

• Liver disease – impaired drug metabolism

• Heart block or bradycardia – metoprolol may worsen the condition

• Hyperkalemia – telmisartan may increase potassium levels

• Hypotension – may cause excessive blood pressure lowering

• Diabetes – may mask symptoms of hypoglycemia

Take Cilnidipine + Metoprolol Succinate (Metoprolol Tartrate) + Telmisartan exactly as prescribed by your doctor. The dosage depends on your blood pressure and overall health. Do not alter the dose without consulting your doctor.

Overdose of Cilnidipine + Metoprolol Succinate (Metoprolol Tartrate) + Telmisartan may lead to severe hypotension, dizziness, fainting, slow heart rate, or kidney dysfunction. Immediate medical attention is required in such cases.

If you miss a dose, take it as soon as you remember. If it is close to your next dose, skip the missed dose and continue your regular schedule. Do not take a double dose to make up for a missed dose.